Approximately 112 million people globally are affected by angina and undergo coronary angiography, the primary diagnostic test for angina.1
Too often patients with ischemia and no obstructive coronary artery disease (INOCA) on angiography — remain undiagnosed.2
Coronary Microvascular Dysfunction (CMD)3 is defined as impaired blood flow to the microcirculation. A clear diagnosis and optimized treatment plan can improve outcomes for these patients at high risk for major adverse events (MACE).4
Ischemia and No Obstructive CAD:
Why bother? – Dr. Tom Ford, Interventional Cardiologist
How a MicroVascular Dysfunction Diagnosis Benefits Patients
The CorMicA (CORonary MICrovascular Angina) study revealed that patients may benefit when CMD is accurately diagnosed and appropriately treated:4
Adequate evaluation and optimal treatment of patients who have INOCA can relieve patient symptoms, improve Quality of Life (QoL) and may reduce healthcare costs.4,6
An accurate CMD diagnosis can help reduce healthcare resource consumption,7 resulting in lower costs for hospitals and patients8 with a savings from $2,100 (Netherlands) to $7,300 (U.S.) per hospitalization avoided (2017 costs).9
An economic analysis of the CorMicA study showed that a comprehensive physiology assessment is cost-effective compared to standard care (medical therapy and cardiac rehabilitation care) at 1-year follow-up.10
Challenges Diagnosing The Underlying Causes Of Chest Pain
Ischemic heart disease continues to be the leading cause of death globally.11 Yet chest pain—while often ischemic in nature—could have many etiologies, as illustrated.3 When chest pain is caused by ischemia, proper management depends on accurately identifying and treating the underlying cause of angina.
STRUCTURAL CAUSES7
In-stent restenosis
Stent thrombosis
Progression of atherosclerotic disease in other segments
Incomplete revascularization
Diffuse atherosclerotic disease without focal stenosis
Presence of myocardial bridges
FUNCTIONAL CAUSES7
Epicardial vasospasm
Coronary microvascular dysfunction
Stent-related mechanical stretch of the arterial wall
The Common Diagnosis of INOCA
Only 41% of patients assessed for angina are found to have obstructive chronic Coronary Artery Disease.13 The majority, 59% of patients, assessed for angina are found to have no angiographic abnormalities, but still have symptoms of a coronary disorder.4,5
20-30% of patients experience recurrent angina in 1 year after percutaneous coronary intervention (PCI).12
Without a clear diagnosis and treatment, patients may experience recurrent hospitalizations, poor functional health, and adverse cardiovascular outcomes.7
*According to the Seattle Angina Questionnaire score.
References
Kunadian, V. et al. An EAPCI Expert Consensus Document on Ischaemic with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal. 2020; 0:1-21.
Jespersen, L. et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734-744. doi:10.1093/eurheartj/ehr331.
Marinescu, MA. et al. Coronary microvascular dysfunction and microvascular angina: a systematic review of therapies. JACC Cardiovasc Imaging. 2015;8:210-220.
Ford, TJ. et al. 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Intv. 2020; 13:33-45.
Patel, MR. et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886-895. doi:10.1056/NEJMoa0907272.
Heggie, R. et al. Stratified medicine using invasive coronary function testing in angina: a cost-effectiveness analysis of the British Heart Foundation CorMicA trial. IJC. 2021; doi: 10.1016/j.ijcard.2021.05.016.
Lee, B. et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131:1054–1060.
Reriani, M. et al. Coronary endothelial function testing may improve long-term quality of life in subjects with microvascular coronary endothelial dysfunction. Open Heart. 2019;6:e000870.
Omerovic, E. et al. FFR-Guided Complete Revascularization During Primary Angioplasty: Effects on Societal Costs. EuroPCR 2017.
Heggie, R. et al. A cost-effectiveness analysis of the BHF CorMicA Trial. Interventional Journal of Cardiology 2021. Doi:10.1016/j.ijcard.2021.05.016.
Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459-544.
Jeremias, A. Post-PCI Physiology: Insights from DEFINE PCI and other Studies Speaker Presentation. TCT 2019.
Maas, A. et al. Microvascular angina: diagnosis, assessment, and treatment. EMJ Int Cardiol. 2019; 7[Suppl 1]2-17.
Please Enter the Pop Up text to be displayed in Pop Up here.
MAT-2002360 v4.0
DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?
CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.
The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.
Do you want to continue?
Yes
The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.
